肺炎支原体肺炎的抗感染与抗炎治疗研究进展  

Anti-infective and anti-inflammatory treatment strategies for Mycoplasma pneumoniae pneumonia

作　　者：程平 张园园[1] 陈志敏[1] Cheng Ping;Zhang Yuanyuan;Chen Zhimin(Department of Pulmonology,Children's Hospital,Zhejiang University School of Medicine,National Clinical Research Center for Child Health,Hangzhou 310052,China;Department of Pediatrics,Sanmen People's Hospital,Taizhou317100,China)

机构地区：[1]浙江大学医学院附属儿童医院呼吸科、国家儿童健康与疾病临床医学研究中心,杭州310052 [2]三门县人民医院儿科,台州317100

出　　处：《国际儿科学杂志》2024年第12期829-833,共5页International Journal of Pediatrics

基　　金：浙江省自然科学基金项目(LY22H100007);浙江省科技厅2024年度浙江省“尖兵”“领雁”研发攻关计划(2024C03177)。

摘　　要：近年来大环内酯类耐药肺炎支原体(macrolide-resistant Mycoplasma pneumoniae,MRMP)感染引起广泛关注,与此同时,重症及难治性肺炎支原体肺炎(Mycoplasma pneumoniae pneumonia,MPP)的病例明显增多,给临床诊疗工作带来了一定的困难。如何早期发现并干预重症和危重症病例的发生发展,避免死亡和后遗症的发生已成为儿科医生面临的严峻挑战和重要课题,其中早期合理的抗感染与抗炎药物的应用是改善预后的关键。该文就MPP的抗感染和抗炎治疗策略作一综述。In recent years,infections caused by macrolide-resistant Mycoplasma pneumoniae(MRMP)have garnered widespread attention.Concurrently,there has been a notable increase in the incidence of severe and refractory Mycoplasma pneumoniae pneumonia(MPP),posing significant challenges to clinical diagnostic and therapeutic practices.The early identification and intervention of severe and critical cases to prevent mortality and sequelae have become a formidable challenge and an important issue for pediatricians.Among these,the judicious application of anti-infective and anti-inflammatory drugs in the early stages is key for improving prognosis.This article aims to provide an review on the anti-infective and anti-inflammatory treatment strategies for MPP.

关 键 词：肺炎支原体 肺炎 抗感染药物 糖皮质激素 儿童 

分 类 号：R72[医药卫生—儿科]